fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Netupitant & palonosetron hydrochloride

All products: Limited Use (codes 561, 562)

Akynzeo · DIN 02468735 · 300 mg & 0.5 mg · capsule

Limited Use, Reason for Use code 561, 562 requiredMarketed · checked November 17, 2026
StatusLimited Use, Reason for Use code 561, 562 required
Write on scriptone applicable Reason for Use code, 561 or 562 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ontario Limited Use criteria, code 561, 562
Reason for Use code 561 In combination with dexamethasone for once per-cycle treatment in adult patients for: - Prevention of acute and delayed nausea and vomting associated with highly emetogenic cancer chemotherapy (HEC). Highly emetogenic chemotherapy (HEC) regimens: - Cisplatin-based chemotherapy where a single daily dose is greater than or equal to 70mg per meter squared - Cisplatin and cyclophosphamide combinations where the single daily dose of cisplatin is greater than or equal to 50mg per meter squared - Non-cisplatin based highly emetogenic chemotherapy (such as those containing anthracycline greater than or equal to 60mg per meter squared plus cyclophosphamide). Dosage: Recommend Netupitant/Palonosetron 300mg/0.5mg orally on Day 1 approximately 1 hour prior to the start of each HEC. Coverage limit: LU Authorization Period: 1 year Reason for Use code 562 In combination with dexamethasone for once per-cycle treatment in adult patients for: - Prevention of acute nausea and vomiting associated with moderately emetogenic cancer therapy (MEC) that is uncontrolled by a 5-hydroxytryptamine-3 (5-HT3) receptor antagonist (RA) alone in a previous cycle. Dosage: Recommend Netupitant/Palonosetron 300mg/0.5mg orally on Day 1 approximately 1 hour prior to the start of each MEC cycle. Coverage limit: LU Authorization Period: 1 year
No interchangeable product listed in the Ontario extract
Akynzeo · DIN 02468735 Manufacturer: Knight Therapeutics Inc.; listing date 2019-06-28 Health Canada: Marketed since 2022-11-30 · brand AKYNZEO · ATC A04AA55 PALONOSETRON, COMBINATIONS · form Capsule · route Oral · ingredients PALONOSETRON (PALONOSETRON HYDROCHLORIDE) 0.5 MG, NETUPITANT 300 MG · company Knight therapeutics inc. · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Akynzeo: Formulary list price $144.01 per unit (the source does not state the unit; exact figure $144.0075). What the ministry pays, not the patient.

Ministry pays: $144.0075 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02468735)

Source record
DIN 02468735: Akynzeo Raw flags: sec12=Y, sec3=Y Item: 562200052; group id 669; item number 1659; lccId 00319; manufacturer id KNT Source form: Cap; strength: 300mg & 0.5mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $144.0075; ministry $144.0075 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02468735 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95721
Shortage status: not checked (no credentials)

Other products in the same Health Canada class (A04A, A04AA): coverage varies; not interchangeable

  • Granisetron (Kytril): limited Use 326, 454, not a benefit
  • Ondansetron (Zofran ODT (Tablet)): limited Use 215, 216, 217, 218, 454, 696, not a benefit
  • Ondansetron (Zofran): not a benefit
  • Nabilone (Cesamet): general benefit, not a benefit
  • Aprepitant (Emend Tri-Pack): limited Use 452, 453
Other drugs in the same formulary class (56:22 Antiemetics and Antinauseants) and how they are covered

Matched class: 56:22 Antiemetics and Antinauseants

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: DOXYLAMINE SUCCINATE AND PYRIDOXINE HCL, MECLIZINE HCL Some products covered without a code (check the product listing): NABILONE 56:22 Antiemetics and Antinauseants

GRANISETRON HCL

· 4 products · Listed, not a benefit (1), Limited Use, codes 91, 92, 93, 326, 454 (3) · strengths: 1mg · Tab

ONDANSETRON HYDROCHLORIDE

· 54 products · Listed, not a benefit (5), Limited Use, codes 215, 216, 217, 218, 454, 696 (49) · strengths: 4mg, 8mg, 4mg/5mL · O/L, Tab

ONDANSETRON HCL DIHYDRATE

· 8 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 2mg/mL · Inj Sol-2mL Pk, Inj Sol-4mL Pk

NABILONE

· 10 products · Off-Formulary Interchangeable, not an ODB benefit (4), General benefit (6) · strengths: 0.25mg, 0.5mg, 1mg · Cap

APREPITANT

· 1 products · Limited Use, codes 452, 453 · strengths: 125mg & 80mg · Cap

DOXYLAMINE SUCCINATE AND PYRIDOXINE HCL

· 4 products · General benefit · strengths: 10mg & 10mg · SR Tab

MECLIZINE HCL

· 1 products · General benefit · strengths: 25mg · Tab

DIMENHYDRINATE

· 2 products · Limited Use, codes 481 · strengths: 50mg/mL · Inj Sol (with Preservative) Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 56:22
Full class listing Related classes: 56:04 Antacids and Adsorbents, 56:08 Antidiarrhea Agents, 56:12 Cathartics, 56:16 Digestants, 56:40 Miscellaneous G.I. Drugs Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE Akynzeo® (netupitant/palonosetron) in combination with dexamethasone, is indicated for once- per-cycle treatment in adult patients for:  Prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy  Prevention of acute nausea and vomiting associated with moderately emetogenic cancer therapy that is uncontrolled by a 5-HT3 receptor antagonist alone Geriatrics (≥ 65 years of age): No dosage adjustment is required in patients ≥ 65 years of age and older. In general, use caution when dosing geriatric patients as they have a greater frequency of decreased hepatic, renal or cardiac function and concomitant disease or other drug therapy. Pediatrics (< 18 years of age): The safety and effectiveness of Akynzeo in patients below the age of 18 years have not been established. No data are available. Page 3 of 36 https://pdf.hres.ca/dpd_pm/00068269.PDF PM date: not printed or not captured Source product: AKYNZEO; DIN 02468735; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.